Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1LG2 | Q9BQ51 | 3/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17788591 | 0.81 | PNMT (0.50) | PDCD1LG2CD274MEN1PKMKMT2A | |
| SCHEMBL16960713 | 0.78 | PNMT (0.44) | CD274KDM4ECYP1A2TSHRALDH1A1 | |
| SCHEMBL17788600 | 0.76 | PDCD1LG2 (0.50) | PDCD1LG2CD274MEN1PKMKMT2A | |
| SCHEMBL3131415 | 0.75 | BCHE (0.46) | PDCD1LG2CD274KMT2AKDM4EADRB2 | |
| SCHEMBL28829256 | 0.75 | GABRA1 (0.54) | PDCD1LG2CD274MEN1PKMKMT2A | |
| SCHEMBL3136060 | 0.75 | ADRB2 (0.42) | PDCD1LG2CD274NPC1KDM4EHTT | |
| SCHEMBL22548784 | 0.74 | KDM4E (0.49) | PDCD1LG2CD274MEN1PKMKMT2A | |
| SCHEMBL13900350 | 0.73 | NPC1 (0.50) | MEN1PKMKMT2ANPC1ADRB2 | |
| SCHEMBL16950743 | 0.72 | GABRA1 (0.50) | CD274HTTALDH1A1 | |
| SCHEMBL22957884 | 0.72 | APOBEC3G (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190125699-A1 | TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN | CIPHER PHARMACEUTICALS INC. (CA) | 2019-05-02 | — | — | US | disclosed |
| US-9907765-B2 | Treatment of connective tissue diseases of the skin | CIPHER PHARMACEUTICALS INC. (CA) | 2018-03-06 | — | — | US | disclosed |
| US-20170157068-A1 | TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN | ASTION PHARMA A/S (DK) | 2017-06-08 | — | — | US | disclosed |
| US-20130237607-A1 | TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN | ASTION DEVELOPMENT A/S (DK) | 2013-09-12 | — | — | US | disclosed |
| US-8426475-B2 | Treatment of connective tissue diseases of the skin | ASTION DEVELOPMENT A/S (DK) | 2013-04-23 | — | — | US | disclosed |
| EP-1719507-B1 | Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin | ASTION DEV AS (DK) | 2010-07-14 | — | — | EP | disclosed |
| WO-2006108424-A9 | BETA-2 ADRENOCEPTOR AGONISTS FOR TREATING CONNECTIVE TISSUE DISEASES OF THE SKIN | ASTION DEV AS (DK) | 2007-08-09 | — | — | WO | disclosed |
| EP-1719507-A1 | Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin | Astion Development A/S (DK) | 2006-11-08 | — | — | EP | disclosed |
| WO-2006108424-A2 | BETA-2 ADRENOCEPTOR AGONISTS FOR TREATING CONNECTIVE TISSUE DISEASES OF THE SKIN | ASTION PHARMA A/S (DK) | 2006-10-19 | — | — | WO | disclosed |
| US-20060235048-A1 | Treatment of connective tissue diseases of the skin | ASTION DEVELOPMENT A/S | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237607-A1 | TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN | ADRB2, ADRB1, ADRA2A | PDCD1LG2 1945/4885CD274 1215/4885MEN1 3155/4885 |
| US-20060235048-A1 | Treatment of connective tissue diseases of the skin | ADRB2, ADRB1, ADRA2A | PDCD1LG2 1945/4885CD274 1215/4885MEN1 3155/4885 |
| US-20170157068-A1 | TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN | ADRB2, ADRB1, ADRA2A | PDCD1LG2 1945/4885CD274 1215/4885MEN1 3155/4885 |
| US-20190125699-A1 | TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN | ADRB2, ADRB1, ADRA2A | PDCD1LG2 1945/4885CD274 1215/4885MEN1 3155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.